{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T18:54:00Z","timestamp":1785437640734,"version":"3.56.0"},"reference-count":60,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,11,2]],"date-time":"2022-11-02T00:00:00Z","timestamp":1667347200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,11,2]],"date-time":"2022-11-02T00:00:00Z","timestamp":1667347200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100000050","name":"National Heart, Lung, and Blood Institute","doi-asserted-by":"publisher","award":["HL141473"],"award-info":[{"award-number":["HL141473"]}],"id":[{"id":"10.13039\/100000050","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["3P30CA013148"],"award-info":[{"award-number":["3P30CA013148"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["R01CA155638"],"award-info":[{"award-number":["R01CA155638"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Ovarian Res"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>A leading theory for ovarian carcinogenesis proposes that inflammation associated with incessant ovulation is a driver of oncogenesis. Consistent with this theory, nonsteroidal anti-inflammatory drugs (NSAIDs) exert promising chemopreventive activity for ovarian cancer. Unfortunately, toxicity is associated with long-term use of NSAIDs due to their cyclooxygenase (COX) inhibitory activity. Previous studies suggest the antineoplastic activity of NSAIDs is COX independent, and rather may be exerted through phosphodiesterase (PDE) inhibition. PDEs represent a unique chemopreventive target for ovarian cancer given that ovulation is regulated by cyclic nucleotide signaling. Here we evaluate PDE10A as a novel therapeutic target for ovarian cancer. Analysis of The Cancer Genome Atlas (TCGA) ovarian tumors revealed PDE10A overexpression was associated with significantly worse overall survival for patients. PDE10A expression also positively correlated with the upregulation of oncogenic and inflammatory signaling pathways. Using small molecule inhibitors, Pf-2545920 and a novel NSAID-derived PDE10A inhibitor, MCI-030, we show that PDE10A inhibition leads to decreased ovarian cancer cell growth and induces cell cycle arrest and apoptosis. We demonstrate these pro-apoptotic properties occur through PKA and PKG signaling by using specific inhibitors to block their activity. PDE10A genetic knockout in ovarian cancer cells through CRISP\/Cas9 editing lead to decreased cell proliferation, colony formation, migration and invasion, and<jats:italic>in vivo<\/jats:italic>tumor growth. We also demonstrate that PDE10A inhibition leads to decreased Wnt-induced \u03b2-catenin nuclear translocation, as well as decreased EGF-mediated activation of RAS\/MAPK and AKT pathways in ovarian cancer cells. These findings implicate PDE10A as novel target for ovarian cancer chemoprevention and treatment.<\/jats:p>","DOI":"10.1186\/s13048-022-01050-9","type":"journal-article","created":{"date-parts":[[2022,11,2]],"date-time":"2022-11-02T14:07:18Z","timestamp":1667398038000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":19,"title":["Phosphodiesterase 10A (PDE10A) as a novel target to suppress \u03b2-catenin and RAS signaling in epithelial ovarian cancer"],"prefix":"10.1186","volume":"15","author":[{"given":"Rebecca M.","family":"Borneman","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elaine","family":"Gavin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alla","family":"Musiyenko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wito","family":"Richter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin J.","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David K.","family":"Crossman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joel F.","family":"Andrews","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annelise M.","family":"Wilhite","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven","family":"McClellan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ileana","family":"Aragon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio B.","family":"Ward","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xi","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adam B.","family":"Keeton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristy","family":"Berry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gary A.","family":"Piazza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer M.","family":"Scalici","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luciana Madeira","family":"da Silva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,11,2]]},"reference":[{"key":"1050_CR1","volume-title":"SEER Cancer Statistics Review, 1975\u20132016","author":"N Howlader","year":"2019","unstructured":"Howlader N, Noone AM, Krapcho M, Miller D, Brest A, Yu M, et al. SEER Cancer Statistics Review, 1975\u20132016. Bethesda: National Cancer Institute; 2019."},{"key":"1050_CR2","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/S0140-6736(10)62110-1","volume":"377","author":"PM Rothwell","year":"2011","unstructured":"Rothwell PM, Fowkes FGR, Belch JF, Ogawa H, Warlow CP, Meade TW. Effect of daily aspirin on long-term risk of death due to cancer: analysis of individual patient data from randomised trials. Lancet. 2011;377:31\u201341 Elsevier Ltd.","journal-title":"Lancet"},{"key":"1050_CR3","doi-asserted-by":"crossref","unstructured":"Qiao Y, Yang T, Gan Y, Li W, Wang C, Gong Y, et al. Associations between aspirin use and the risk of cancers: a meta-analysis of observational studies. BMC Cancer. 2018;18:288. BioMed Central Ltd.","DOI":"10.1186\/s12885-018-4156-5"},{"key":"1050_CR4","doi-asserted-by":"crossref","unstructured":"Zhang D, Bai B, Xi Y, Wang T, Zhao Y. Is aspirin use associated with a decreased risk of ovarian cancer? A systematic review and meta-analysis of observational studies with dose-response analysis. Gynecol Oncol. 2016;142(2):368\u201377. Academic Press Inc.","DOI":"10.1016\/j.ygyno.2016.04.543"},{"key":"1050_CR5","doi-asserted-by":"publisher","first-page":"1839","DOI":"10.1007\/s10552-012-0063-2","volume":"23","author":"MA Murphy","year":"2012","unstructured":"Murphy MA, Trabert B, Yang HP, Park Y, Brinton LA, Hartge P, et al. Non-steroidal anti-inflammatory drug use and ovarian cancer risk: findings from the NIH-AARP Diet and Health Study and systematic review. Cancer Causes Control. 2012;23:1839\u201352.","journal-title":"Cancer Causes Control"},{"key":"1050_CR6","doi-asserted-by":"crossref","unstructured":"Trabert B, Ness RB, Lo-Ciganic WH, Murphy MA, Goode EL, Poole EM, et al. Aspirin, nonaspirin nonsteroidal anti-inflammatory drug, and acetaminophen use and risk of invasive epithelial ovarian cancer: a pooled analysis in the ovarian cancer association consortium. J Natl Cancer Inst. 2014;106:djt431.","DOI":"10.1093\/jnci\/djt431"},{"key":"1050_CR7","doi-asserted-by":"publisher","first-page":"293","DOI":"10.17772\/gp\/1579","volume":"84","author":"R Kisielewski","year":"2013","unstructured":"Kisielewski R, To\u0142wi\u0144ska A, Mazurek A, Lauda\u0144ski P. Inflammation and ovarian cancer-current views. Ginekol Pol. 2013;84:293\u20137.","journal-title":"Ginekol Pol"},{"issue":"1","key":"1050_CR8","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1097\/AOG.0b013e318291c235","volume":"122","author":"LJ Havrilesky","year":"2013","unstructured":"Havrilesky LJ, Moorman PG, Lowery WJ, Gierisch JM, Coeytaux RR, Urrutia RP, et al. Oral contraceptive pills as primary prevention for ovarian cancer: a systematic review and meta-analysis. Obstet Gynecol. 2013;122(1):139\u201347.","journal-title":"Obstet Gynecol"},{"key":"1050_CR9","doi-asserted-by":"publisher","first-page":"821","DOI":"10.18433\/J3VW2F","volume":"16","author":"S Harirforoosh","year":"2013","unstructured":"Harirforoosh S, Asghar W, Jamali F. Adverse effects of nonsteroidal antiinflammatory drugs: an update of gastrointestinal, cardiovascular and renal complications. J Pharm Pharm Sci. 2013;16:821\u201347.","journal-title":"J Pharm Pharm Sci"},{"key":"1050_CR10","doi-asserted-by":"publisher","first-page":"1104","DOI":"10.1158\/1078-0432.CCR-13-1573","volume":"20","author":"E Gurpinar","year":"2014","unstructured":"Gurpinar E, Grizzle WE, Piazza GA. NSAIDs inhibit tumorigenesis, but how? Clin Cancer Res. 2014;20:1104\u201313.","journal-title":"Clin Cancer Res"},{"issue":"13","key":"1050_CR11","first-page":"3338","volume":"60","author":"WJ Thompson","year":"2000","unstructured":"Thompson WJ, Piazza GA, Li H, Liu L, Fetter J, Zhu B, et al. Exisulind induction of apoptosis involves guanosine 3,5-Cyclic monophosphate phosphodiesterase inhibition, protein Kinase G activation, and attenuated-catenin. Cancer Res. 2000;60(13):3338\u201342.","journal-title":"Cancer Res"},{"key":"1050_CR12","doi-asserted-by":"crossref","unstructured":"Li N, Xi Y, Tinsley HN, Gurpinar E, Gary BD, Zhu B, et al. Sulindac selectively inhibits colon tumor cell growth by activating the cGMP\/PKG pathway to suppress Wnt\/\u03b2-catenin signaling.\u00a0Mol Cancer Ther.\u00a02014;12:1848\u201359.","DOI":"10.1158\/1535-7163.MCT-13-0048"},{"key":"1050_CR13","doi-asserted-by":"publisher","first-page":"3331","DOI":"10.1158\/1535-7163.MCT-09-0758","volume":"8","author":"HN Tinsley","year":"2009","unstructured":"Tinsley HN, Gary BD, Keeton AB, Zhang W, Abadi AH, Reynolds RC, et al. Sulindac sulfide selectively inhibits growth and induces apoptosis of human breast tumor cells by phosphodiesterase 5 inhibition, elevation of cyclic GMP, and activation of protein kinase G. Mol Cancer Ther. 2009;8:3331\u201340.","journal-title":"Mol Cancer Ther"},{"key":"1050_CR14","doi-asserted-by":"publisher","first-page":"1303","DOI":"10.1158\/1940-6207.CAPR-10-0030","volume":"3","author":"HN Tinsley","year":"2010","unstructured":"Tinsley HN, Gary BD, Thaiparambil J, Li N, Lu W, Li Y, et al. Colon tumor cell growth-inhibitory activity of sulindac sulfide and other nonsteroidal anti-inflammatory drugs is associated with phosphodiesterase 5 inhibition. Cancer Prev Res. 2010;3:1303\u201313.","journal-title":"Cancer Prev Res"},{"key":"1050_CR15","doi-asserted-by":"publisher","first-page":"572","DOI":"10.1158\/1940-6207.CAPR-09-0001","volume":"2","author":"GA Piazza","year":"2009","unstructured":"Piazza GA, Keeton AB, Tinsley HN, Gary BD, Whitt JD, Mathew B, et al. A novel sulindac derivative that does not inhibit cyclooxygenases but potently inhibits colon tumor cell growth and induces apoptosis with antitumor activity. Cancer Prev Res. 2009;2:572\u201380.","journal-title":"Cancer Prev Res"},{"key":"1050_CR16","doi-asserted-by":"publisher","first-page":"822","DOI":"10.1158\/1940-6207.CAPR-11-0559","volume":"5","author":"JD Whitt","year":"2012","unstructured":"Whitt JD, Li N, Tinsley HN, Chen X, Zhang W, Li Y, et al. A novel sulindac derivative that potently suppresses colon tumor cell growth by inhibiting cGMP phosphodiesterase and \u03b2-catenin transcriptional activity. Cancer Prev Res. 2012;5:822\u201333.","journal-title":"Cancer Prev Res"},{"key":"1050_CR17","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1158\/1535-7163.MCT-12-0785","volume":"12","author":"E Gurpinar","year":"2013","unstructured":"Gurpinar E, Grizzle WE, Shacka JJ, Mader BJ, Li N, Piazza NA, et al. A novel sulindac derivative inhibits lung adenocarcinoma cell growth through suppression of Akt\/mTOR signaling and induction of autophagy. Mol Cancer Ther. 2013;12:663\u201374.","journal-title":"Mol Cancer Ther"},{"key":"1050_CR18","doi-asserted-by":"crossref","unstructured":"Li N, Chen X, Zhu B, Ram\u00edrez-Alc\u00e1ntara V, Canzoneri JC, Lee K, et al. Suppression of \u03b2-catenin\/TCF transcriptional activity and colon tumor cell growth by dual inhibition of PDE5 and 10. Oncotarget. 1025;6(29):27403\u201315.","DOI":"10.18632\/oncotarget.4741"},{"key":"1050_CR19","doi-asserted-by":"publisher","first-page":"488","DOI":"10.1124\/pr.58.3.5","volume":"58","author":"AT Bender","year":"2006","unstructured":"Bender AT, Beavo JA. Cyclic nucleotide phosphodiesterases: Molecular regulation to clinical use. Pharmacol Rev. 2006;58:488\u2013520.","journal-title":"Pharmacol Rev"},{"key":"1050_CR20","doi-asserted-by":"publisher","first-page":"436","DOI":"10.3390\/cancers6010436","volume":"6","author":"AM Fajardo","year":"2014","unstructured":"Fajardo AM, Piazza GA, Tinsley HN. The role of cyclic nucleotide signaling pathways in cancer: targets for prevention and treatment. Cancers. 2014;6:436\u201358.","journal-title":"Cancers"},{"key":"1050_CR21","doi-asserted-by":"crossref","unstructured":"Peng T, Gong J, Jin Y, Zhou Y, Tong R, Wei X, et al. Inhibitors of phosphodiesterase as cancer therapeutics. Eur J Med Chem 2018:742\u201356. Elsevier Masson SAS.","DOI":"10.1016\/j.ejmech.2018.03.046"},{"key":"1050_CR22","doi-asserted-by":"publisher","first-page":"112341","DOI":"10.18632\/oncotarget.22866","volume":"8","author":"S Gong","year":"2017","unstructured":"Gong S, Chen Y, Meng F, Zhang Y, Wu H, Wu F. Roflumilast restores cAMP\/PKA\/CREB signaling axis for FtMtmediated tumor inhibition of ovarian cancer. Oncotarget. 2017;8:112341\u201353.","journal-title":"Oncotarget"},{"key":"1050_CR23","doi-asserted-by":"crossref","unstructured":"Gong S, Chen Y, Meng F, Zhang Y, Li C, Zhang G, et al. Roflumilast enhances cisplatin-sensitivity and reverses cisplatin-resistance of ovarian cancer cells via cAMP\/PKA\/CREB-FtMt signalling axis. Cell Proliferation. 2018;51:e12474.","DOI":"10.1111\/cpr.12474"},{"key":"1050_CR24","doi-asserted-by":"publisher","first-page":"981","DOI":"10.1016\/j.bcp.2004.05.026","volume":"68","author":"L Hirsh","year":"2004","unstructured":"Hirsh L, Dantes A, Suh BS, Yoshida Y, Hosokawa K, Tajima K, et al. Phosphodiesterase inhibitors as anti-cancer drugs. Biochem Pharmacol. 2004;68:981\u20138.","journal-title":"Biochem Pharmacol"},{"key":"1050_CR25","doi-asserted-by":"publisher","first-page":"995","DOI":"10.1158\/1940-6207.CAPR-21-0208","volume":"14","author":"KJ Lee","year":"2021","unstructured":"Lee KJ, Chang W-CL, Chen X, Valiyaveettil J, Ramirez-Alcantara V, Gavin E, et al. Suppression of colon tumorigenesis in mutant Apc mice by a novel PDE10 inhibitor that reduces oncogenic \u03b2-Catenin. Cancer Prev Res (Phila). 2021;14:995\u20131008. https:\/\/doi.org\/10.1158\/1940-6207.CAPR-21-0208.","journal-title":"Cancer Prev Res (Phila)"},{"key":"1050_CR26","doi-asserted-by":"publisher","first-page":"69264","DOI":"10.18632\/oncotarget.20566","volume":"8","author":"B Zhu","year":"2017","unstructured":"Zhu B, Lindsey A, Li N, Lee K, Ramirez-Alcantara V, Canzoneri JC, et al. Phosphodiesterase 10A is overexpressed in lung tumor cells and inhibitors selectively suppress growth by blocking \u03b2-catenin and MAPK signaling. Oncotarget. 2017;8:69264\u201380 Impact Journals LLC.","journal-title":"Oncotarget"},{"key":"1050_CR27","doi-asserted-by":"publisher","first-page":"1499","DOI":"10.1038\/onc.2014.94","volume":"34","author":"N Li","year":"2014","unstructured":"Li N, Lee K, Xi Y, Zhu B, Gary BD, Ram\u00edrez-Alc\u00e1ntara V, et al. Phosphodiesterase 10A: a novel target for selective inhibition of colon tumor cell growth and \u03b2-catenin-dependent TCF transcriptional activity. Oncogene. 2014;34:1499\u2013509 Nature Publishing Group.","journal-title":"Oncogene"},{"key":"1050_CR28","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1016\/j.mce.2015.01.004","volume":"403","author":"TS Petersen","year":"2015","unstructured":"Petersen TS, Kristensen SG, Jeppesen JV, Gr\u00f8ndahl ML, Wissing ML, Macklon KT, et al. Distribution and function of 3\u2019,5\u2019-Cyclic-AMP phosphodiesterases in the human ovary. Mol Cell Endocrinol. 2015;403:10\u201320 Elsevier Ireland Ltd.","journal-title":"Mol Cell Endocrinol"},{"key":"1050_CR29","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1016\/j.coph.2011.10.004","volume":"11","author":"M Conti","year":"2011","unstructured":"Conti M. Phosphodiesterases and regulation of female reproductive function. Curr Opin Pharmacol. 2011;11:665\u20139 Elsevier Ltd.","journal-title":"Curr Opin Pharmacol"},{"key":"1050_CR30","doi-asserted-by":"crossref","unstructured":"Yang F, Wang M, Zhang B, Xiang W, Zhang K, Chu M, et al. Identification of new progestogen-associated networks in mammalian ovulation using bioinformatics. BMC Syst Biol. 2018;12:36. BioMed Central Ltd.","DOI":"10.1186\/s12918-018-0577-7"},{"key":"1050_CR31","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1158\/2159-8290.CD-12-0095","volume":"2","author":"E Cerami","year":"2012","unstructured":"Cerami E, Gao J, Dogrusoz U, Gross BE, Sumer SO, Aksoy BA, et al. The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. Cancer Discov. 2012;2:401\u20134.","journal-title":"Cancer Discov"},{"key":"1050_CR32","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1126\/scisignal.2004088","volume":"6","author":"J Gao","year":"2013","unstructured":"Gao J, Aksoy BA, Dogrusoz U, Dresdner G, Gross B, Sumer SO, et al. Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal. Science Signaling. 2013;6:1\u201320.","journal-title":"Science Signaling"},{"key":"1050_CR33","doi-asserted-by":"publisher","first-page":"3200","DOI":"10.1158\/0008-5472.CAN-19-4044","volume":"80","author":"H Huang","year":"2020","unstructured":"Huang H, Wang Y, Kandpal M, Zhao G, Cardenas H, Ji Y, et al. FTO-Dependent N6-Methyladenosine modifications inhibit ovarian cancer stem cell self-renewal by blocking cAMP signaling. Cancer Res. 2020;80:3200\u201314 American Association for Cancer Research.","journal-title":"Cancer Res"},{"key":"1050_CR34","doi-asserted-by":"crossref","unstructured":"Mizuno H, Kitada K, Nakai K, Sarai A. PrognoScan: a new database for meta-analysis of the prognostic value of genes. BMC Medical Genomics. 2009;2:18.","DOI":"10.1186\/1755-8794-2-18"},{"key":"1050_CR35","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.274.26.18438","volume-title":"Cloning and characterization of a novel human phosphodiesterase that hydrolyzes both cAMP and cGMP (PDE10A)*","author":"K Fujishige","year":"1999","unstructured":"Fujishige K, Kotera J, Michibata H, Yuasa K, Takebayashi S-I, Okumura K, et al. Cloning and characterization of a novel human phosphodiesterase that hydrolyzes both cAMP and cGMP (PDE10A)*. 1999."},{"key":"1050_CR36","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1042\/BJ20131681","volume":"459","author":"M Xie","year":"2014","unstructured":"Xie M, Blackman B, Scheitrum C, Mika D, Blanchard E, Lei T, et al. The upstream conserved regions (UCRs) mediate homo- and hetero-oligomerization of type 4 cyclic nucleotide phosphodiesterases (PDE4s). Biochem J. 2014;459:539\u201350.","journal-title":"Biochem J"},{"key":"1050_CR37","doi-asserted-by":"publisher","first-page":"5188","DOI":"10.1021\/jm900521k","volume":"52","author":"PR Verhoest","year":"2009","unstructured":"Verhoest PR, Chapin DS, Corman M, Fonseca K, Harms JF, Hou X, et al. Discovery of a novel class of phosphodiesterase 10A inhibitors and identification of clinical candidate 2-[4-(1-methyl-4-pyridin-4-yl-1H-pyrazol-3- yl)-phenoxymethyl]-quinoline (PF-2545920) for the treatment of schizophrenia. J Med Chem. 2009;52:5188\u201396.","journal-title":"J Med Chem"},{"key":"1050_CR38","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1146\/annurev.cellbio.19.050103.103356","volume":"19","author":"M Krause","year":"2003","unstructured":"Krause M, Dent EW, Bear JE, Loureiro JJ, Gertler FB. Ena\/VASP proteins: regulators of the actin cytoskeleton and cell migration. Annu Rev Cell Dev Biol. 2003;19:541\u201364.","journal-title":"Annu Rev Cell Dev Biol"},{"key":"1050_CR39","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.lfs.2014.12.018","volume":"123","author":"M Ali","year":"2015","unstructured":"Ali M, Rogers LK, Pitari GM. Serine phosphorylation of vasodilator-stimulated phosphoprotein (VASP) regulates colon cancer cell survival and apoptosis. Life Sci. 2015;123:1\u20138 Elsevier Inc.","journal-title":"Life Sci"},{"key":"1050_CR40","first-page":"803","volume":"1","author":"A Deguchi","year":"2002","unstructured":"Deguchi A, Soh JW, Li H, Pamukcu R, Thompson WJ, Weinstein IB. Vasodilator-stimulated phosphoprotein (VASP) phosphorylation provides a biomarker for the action of exisulind and related agents that activate protein kinase G. Mol Cancer Ther. 2002;1:803\u20139.","journal-title":"Mol Cancer Ther"},{"key":"1050_CR41","doi-asserted-by":"crossref","first-page":"189","DOI":"10.7555\/JBR.31.20160133","volume":"31","author":"K Lee","year":"2017","unstructured":"Lee K, Piazza GA. The interaction between the Wnt\/\u03b2-catenin signaling cascade and PKG activation in cancer. J Biomed Res. 2017;31:189\u201396.","journal-title":"J Biomed Res"},{"key":"1050_CR42","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/j.gde.2006.12.007","volume":"17","author":"P Polakis","year":"2007","unstructured":"Polakis P. The many ways of Wnt in cancer. Curr Opin Genet Dev. 2007;17:45\u201351.","journal-title":"Curr Opin Genet Dev"},{"key":"1050_CR43","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1016\/j.cell.2006.10.018","volume":"127","author":"H Clevers","year":"2006","unstructured":"Clevers H. Wnt\/\u03b2-Catenin signaling in development and disease. Cell. 2006;127:469\u201380.","journal-title":"Cell"},{"key":"1050_CR44","first-page":"8664","volume":"61","author":"T Zhang","year":"2001","unstructured":"Zhang T, Otevrel T, Gao Z, Gao Z, Ehrlich SM, Fields JZ, et al. Evidence that APC regulates survivin expression: a possible mechanism contributing to the stem cell origin of colon cancer. Can Res. 2001;61:8664\u20137.","journal-title":"Can Res"},{"key":"1050_CR45","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1038\/18884","volume":"398","author":"O Tetsu","year":"1999","unstructured":"Tetsu O, McCormick F. \u03b2-catenin regulates expression of cyclin D1 in colon carcinoma cells. Nature. 1999;398:422\u20136.","journal-title":"Nature"},{"key":"1050_CR46","doi-asserted-by":"publisher","first-page":"1509","DOI":"10.1126\/science.281.5382.1509","volume":"281","author":"TC He","year":"1998","unstructured":"He TC, Sparks AB, Rago C, Hermeking H, Zawel L, Da Costa LT, et al. Identification of c-MYC as a target of the APC pathway. Science. 1998;281:1509\u201312.","journal-title":"Science"},{"issue":"22","key":"1050_CR47","doi-asserted-by":"publisher","first-page":"3122","DOI":"10.1038\/sj.onc.1210407","volume":"26","author":"ZG Goldsmith","year":"2007","unstructured":"Goldsmith ZG, Dhanasekaran DN. G Protein regulation of MAPK networks. Oncogene. 2007;26(22):3122\u201342.","journal-title":"Oncogene"},{"key":"1050_CR48","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1006\/gyno.2001.6280","volume":"82","author":"AST Wong","year":"2001","unstructured":"Wong AST, Kim SO, Leung PCK, Auersperg N, Pelech SL. Profiling of protein kinases in the neoplastic transformation of human ovarian surface epithelium. Gynecol Oncol. 2001;82:305\u201311.","journal-title":"Gynecol Oncol"},{"key":"1050_CR49","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13048-018-0467-z","volume":"11","author":"W Li","year":"2018","unstructured":"Li W, Liu Z, Liang B, Chen S, Zhang X, Tong X, et al. Identification of core genes in ovarian cancer by an integrative meta-analysis. J Ovarian Res. 2018;11:1\u20139.","journal-title":"J Ovarian Res"},{"key":"1050_CR50","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/1755-8794-1-43","volume":"1","author":"C Cheadle","year":"2008","unstructured":"Cheadle C, Nesterova M, Watkins T, Barnes KC, Hall JC, Rosen A, et al. Regulatory subunits of PKA define an axis of cellular proliferation\/differentiation in ovarian cancer cells. BMC Med Genomics. 2008;1:1\u201314.","journal-title":"BMC Med Genomics"},{"issue":"5","key":"1050_CR51","doi-asserted-by":"publisher","first-page":"5353","DOI":"10.18632\/oncotarget.6705","volume":"7","author":"K Lee","year":"2015","unstructured":"Lee K, Lindsey AS, Li N, Gary B, Andrews J, Keeton AB, et al. \u03b2-catenin nuclear translocation in colorectal cancer cells is suppressed by PDE10A inhibition, cGMP elevation, and activation of PKG. Oncotarget. 2015;7(5):5353\u201365.","journal-title":"Oncotarget"},{"key":"1050_CR52","doi-asserted-by":"crossref","unstructured":"Hunzicker-Dunn M, Mayo K. Gonadotropin Signaling in the Ovary. Third Edit. Knobil and Neill\u2019s Physiology of Reproduction. 3rd ed. Elsevier Inc.; 2006.","DOI":"10.1016\/B978-012515400-0\/50019-1"},{"key":"1050_CR53","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1530\/jrf.0.0590351","volume":"59","author":"CJ Hubbard","year":"1980","unstructured":"Hubbard CJ, Carolina N, Sa U. Ovarian cAMP and cGMP fluctuations in the hamster during the oestrous cycle. J Reprod Fertil. 1980;59:351\u20135.","journal-title":"J Reprod Fertil"},{"key":"1050_CR54","doi-asserted-by":"publisher","first-page":"7071","DOI":"10.1073\/pnas.96.12.7071","volume":"96","author":"SH Soderling","year":"1999","unstructured":"Soderling SH, Bayuga SJ, Beavo JA. Isolation and characterization of a dual-substrate phosphodiesterase gene family: PDE10A. Proc Natl Acad Sci USA. 1999;96:7071\u20136.","journal-title":"Proc Natl Acad Sci USA"},{"key":"1050_CR55","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1042\/BSR20190405","volume":"39","author":"Y Wu","year":"2019","unstructured":"Wu Y, Cai Q, Li W, Cai Z, Liu Y, Li H, et al. Active PKG II inhibited the growth and migration of ovarian cancer cells through blocking Raf\/MEK and PI3K\/Akt signaling pathways. Biosci Rep. 2019;39:1\u201310.","journal-title":"Biosci Rep"},{"key":"1050_CR56","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/j.niox.2009.11.007","volume":"22","author":"K Mujoo","year":"2010","unstructured":"Mujoo K, Sharin VG, Martin E, Choi BK, Sloan C, Nikonoff LE, et al. Role of soluble guanylyl cyclase-cyclic GMP signaling in tumor cell proliferation. Nitric Oxide. 2010;22:43\u201350 Elsevier Inc.","journal-title":"Nitric Oxide"},{"key":"1050_CR57","first-page":"729","volume":"25","author":"H Xu","year":"2020","unstructured":"Xu H, Zhang Z, Li P, Lu X, Chen B, Lan T. Expression of PKG2 in ovarian cancer and its effect on epidermal growth factor receptor. J BUON. 2020;25:729\u201335.","journal-title":"J BUON"},{"key":"1050_CR58","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13048-019-0596-z","volume":"12","author":"VHL Nguyen","year":"2019","unstructured":"Nguyen VHL, Hough R, Bernaudo S, Peng C. Wnt\/\u03b2-catenin signalling in ovarian cancer: insights into its hyperactivation and function in tumorigenesis. J Ovarian Res. 2019;12:1\u201317.","journal-title":"J Ovarian Res"},{"key":"1050_CR59","doi-asserted-by":"publisher","first-page":"23720","DOI":"10.18632\/oncotarget.4690","volume":"6","author":"AB Nagaraj","year":"2015","unstructured":"Nagaraj AB, Joseph P, Kovalenko O, Singh S, Armstrong A, Redline R, et al. Critical role of Wnt\/\u00df-catenin signaling in driving epithelial ovarian cancer platinum resistance. Oncotarget. 2015;6:23720\u201334.","journal-title":"Oncotarget"},{"key":"1050_CR60","doi-asserted-by":"crossref","unstructured":"Pilz Modem Suhasini RB, Li H, Lohmann SM. Cyclic-GMP-dependent protein kinase inhibits the ras\/mitogen-activated protein kinase pathway. Mol Cell Biol.\u00a01998;18(12):6983\u201394.","DOI":"10.1128\/MCB.18.12.6983"}],"container-title":["Journal of Ovarian Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13048-022-01050-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13048-022-01050-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13048-022-01050-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,11]],"date-time":"2023-03-11T00:12:37Z","timestamp":1678493557000},"score":1,"resource":{"primary":{"URL":"https:\/\/ovarianresearch.biomedcentral.com\/articles\/10.1186\/s13048-022-01050-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11,2]]},"references-count":60,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["1050"],"URL":"https:\/\/doi.org\/10.1186\/s13048-022-01050-9","relation":{},"ISSN":["1757-2215"],"issn-type":[{"value":"1757-2215","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,11,2]]},"assertion":[{"value":"15 October 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 October 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 November 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"G.A. Piazza, A.B. Keeton, and X. Chen are co-founders of ADT Pharmaceuticals Inc. and consultants. No other authors have any competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"120"}}